Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8120650 | 0.77 | CA1 (0.38) | ALDH1A1HPGDALOX15HIF1AHSD17B10 | |
| SCHEMBL6936844 | 0.77 | ACHE (0.30) | — | |
| SCHEMBL31128246 | 0.67 | LMNA (0.37) | — | |
| SCHEMBL30631398 | 0.64 | CCR1 (0.38) | — | |
| SCHEMBL31613426 | 0.64 | — | — | |
| SCHEMBL9281014 | 0.64 | CCR1 (0.33) | — | |
| SCHEMBL20704342 | 0.61 | PLAU (0.39) | — | |
| SCHEMBL6115897 | 0.60 | ALDH1A1 (0.62) | ALDH1A1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5588454 | 0.60 | ALDH1A1 (0.48) | ALDH1A1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11682268 | 0.60 | CA1 (0.53) | ALDH1A1TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400571-A1 | 5,6 UNSATURATED BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024249539-A1 | 5,6 UNSATURATED BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-9725459-B2 | 3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I | GRUNENTHAL GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-3140309-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| EP-3134414-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES II | Grünenthal GmbH (DE) | 2017-03-01 | — | — | EP | disclosed |
| WO-2015161924-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES II | Grünenthal GmbH (DE) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015161928-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307507-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | Grünenthal GmbH (DE) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307507-A1 | 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I | CTSK, OPRK1, CAT | ALDH1A1 886/4885TP53 3218/4885CYP1A2 1458/4885 |
| US-20240400571-A1 | 5,6 UNSATURATED BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | NOD1, NLRP3, FABP3 | ALDH1A1 3965/4885TP53 3159/4885CYP1A2 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.